[
  {
    "question": "Scenario of NF",
    "option_a": "",
    "option_b": "('Infectious etiology')\u2014the marked answer\u2014is incorrect because there is no causal link between infectious agents and NF. Similarly, options suggesting autoimmune mechanisms, environmental toxin exposure, or sporadic non\u2010genetic tumors are inconsistent with the genetic origin of NF.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neurogenetics",
    "explanation": "Neurofibromatosis (NF) is a group of inherited neurocutaneous disorders most notably characterized by the development of benign tumors (neurofibromas), skin pigmentation changes (such as caf\u00e9-au-lait spots), and other systemic manifestations. The underlying principle is that NF is caused by genetic mutations (in the NF1 or NF2 genes), leading to loss of function in tumor-suppressor proteins. Mutations in the NF1 gene (in NF1) result in a deficiency of neurofibromin, a protein that normally negatively regulates the RAS/MAPK pathway. This loss leads to abnormal cell growth and tumor formation. In NF2, mutations lead to merlin protein loss, predisposing to schwannomas. There is no evidence supporting an infectious, autoimmune, or environmentally triggered mechanism for these conditions. Patients with NF typically show clinical findings such as multiple caf\u00e9-au-lait macules, cutaneous neurofibromas, freckling in the axillary or inguinal regions, Lisch nodules on the iris, and sometimes bony dysplasias. The presence of these clinical findings strongly correlates with the underlying genetic mutation and autosomal dominant inheritance pattern. The diagnosis is primarily clinical, using the NIH criteria for NF1 (which include the presence of six or more caf\u00e9-au-lait spots, axillary/inguinal freckling, two or more neurofibromas or one plexiform neurofibroma, optic pathway glioma, distinctive osseous lesions, or a first-degree relative with NF1). Differential diagnoses include other neurocutaneous syndromes such as Legius syndrome. Genetic testing is available but is most often used when the clinical picture is ambiguous. Management is multidisciplinary and includes periodic surveillance for complications (tumor progression, learning disabilities, skeletal abnormalities) and surgical intervention when necessary. Recent advances include targeted therapies such as MEK inhibitors (e.g., selumetinib) for inoperable plexiform neurofibromas in NF1. In pregnancy and lactation, careful monitoring is warranted because hormonal changes can affect tumor growth; genetic counseling is recommended for family planning. Option 'Genetic basis' directly relates to the established etiology of NF and is correct. Option B ('Infectious etiology')\u2014the marked answer\u2014is incorrect because there is no causal link between infectious agents and NF. Similarly, options suggesting autoimmune mechanisms, environmental toxin exposure, or sporadic non\u2010genetic tumors are inconsistent with the genetic origin of NF. \u2022 NF is primarily an autosomal dominant genetic disorder with characteristic cutaneous and systemic findings. \u2022 The presence of multiple caf\u00e9-au-lait spots, neurofibromas, and Lisch nodules are key clinical clues. \u2022 Thorough family and clinical history help in confirming the diagnosis. Recent research and clinical guidelines underscore the role of genetic mutations in NF. New therapeutic approaches, including the use of MEK inhibitors for NF1 plexiform neurofibromas, are emerging, reinforcing the need for genetic confirmation and multidisciplinary management.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Patient has 7 flat brown lesion",
    "option_a": "correctly links the presence of multiple caf\u00e9",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neurogenetics",
    "explanation": "Caf\u00e9-au-lait macules are uniformly pigmented, flat brown lesions that are a cardinal cutaneous feature of Neurofibromatosis type 1 (NF1). The presence of six or more of these lesions (especially in prepubertal children) is one of the major diagnostic criteria for NF1. In NF1, a mutation in the NF1 gene leads to deficient production of neurofibromin, causing abnormal melanocyte activity that manifests as caf\u00e9-au-lait spots along with other neurocutaneous abnormalities. Clinically, the identification of 7 flat brown lesions (caf\u00e9-au-lait spots) strongly suggests NF1, especially when accompanied by other findings such as neurofibromas or axillary freckling. This presentation sets NF1 apart from other conditions with pigmentary skin changes. Diagnosis relies on the NIH criteria for NF1, which include the presence of multiple caf\u00e9-au-lait macules, neurofibromas, and other clinical markers. Differential diagnoses include conditions like McCune-Albright syndrome (which typically presents with irregular caf\u00e9-au-lait spots and endocrine abnormalities) and post-inflammatory hyperpigmentation, which do not meet the criteria for NF1. Management entails lifelong surveillance for complications such as optic pathway gliomas, skeletal abnormalities, and learning disabilities. Multidisciplinary management is key, and in pregnancy, NF1 patients require careful follow-up because hormonal changes can affect tumor behavior. Genetic counseling is recommended. Option A correctly links the presence of multiple caf\u00e9-au-lait spots with NF1. Other less related diagnostic options (e.g., those that might suggest tuberous sclerosis or McCune-Albright syndrome) are not consistent with the described lesion characteristics and are thereby excluded. \u2022 The presence of 6 or more caf\u00e9-au-lait spots is a major diagnostic criterion for NF1. \u2022 Caf\u00e9-au-lait spots in NF1 are typically smooth-bordered (\"coast of California\") as opposed to the irregular borders seen in McCune-Albright syndrome. \u2022 A detailed skin examination is crucial for early diagnosis. Current guidelines and research continue to validate the NIH criteria for NF1 diagnosis. There is also increasing emphasis on early intervention strategies to manage neurodevelopmental and skeletal complications associated with NF1.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Patient with Hypokalemic periodic paralysis; K=2.6, after you give potassium to the patient what is the treatment?",
    "option_a": "daily potassium supplement",
    "option_b": "Acetazolamide",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neurogenetics",
    "explanation": "Hypokalemic periodic paralysis is a neuromuscular disorder characterized by episodic muscle weakness associated with low serum potassium levels. After acute potassium replacement during an attack, long-term prophylactic treatment is aimed at reducing the frequency and severity of future episodes. This condition is typically classified as a channelopathy, often caused by genetic mutations in ion channels (commonly CACNA1S or SCN4A genes) that result in abnormal potassium flux, leading to transient depolarization failure of muscle cells. The resultant hypokalemia precipitates the paroxysmal weakness. During an attack, patients experience sudden onset of muscle weakness, which may range from mild to severe (occasionally involving respiratory muscles), along with laboratory evidence of hypokalemia. Recognizing triggers (e.g., high carbohydrate meals, strenuous exercise) is critical to management. Diagnosis is primarily clinical, supported by laboratory findings of hypokalemia during episodes. Differential diagnoses include hyperkalemic periodic paralysis (characterized by high serum potassium levels) and other neuromuscular disorders such as myasthenia gravis, which can be differentiated by their distinct clinical and laboratory profiles. Acute management involves careful potassium supplementation to correct hypokalemia. For long-term prophylaxis, acetazolamide, a carbonic anhydrase inhibitor, is considered first-line therapy as it reduces attack frequency. Alternatives like dichlorphenamide are second-line. In pregnant patients, potassium repletion is generally safe, while acetazolamide is used with caution (categorized as FDA Category C) after a risk\u2013benefit discussion; in lactation, careful monitoring is advised. Option A (daily potassium supplement) may help maintain serum levels but does not effectively prevent attacks. Option B (Acetazolamide) is established as the first-line prophylactic treatment for reducing attack frequency. The remaining options (C and D) are unspecified and not relevant in this context, making acetazolamide the correct choice. \u2022 Acetazolamide is the mainstay prophylactic treatment in familial hypokalemic periodic paralysis. \u2022 Always differentiate between primary and secondary causes (e.g., thyrotoxic periodic paralysis). \u2022 Monitor serum potassium levels during acute attacks to avoid complications. Recent studies continue to support the use of acetazolamide as a first-line prophylactic agent in hypokalemic periodic paralysis. Emerging data on dichlorphenamide and individualized dosing strategies are also contributing to a more tailored management approach.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "MELAS case with Tic manifestation",
    "option_a": "Skin biopsy",
    "option_b": "Muscle Biopsy",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neurogenetics",
    "explanation": "MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes) is a mitochondrial disorder that typically presents with a complex spectrum of neurological and systemic manifestations. Histopathologic confirmation via muscle biopsy is a well-established diagnostic tool. MELAS is most commonly linked to mitochondrial DNA mutations (notably the m.3243A>G mutation) that impair oxidative phosphorylation. This defect leads to energy production failure, resulting in lactic acidosis and multi-organ involvement, including the brain and muscles. The characteristic mitochondrial pathology includes ragged-red fibers on muscle biopsy. Patients with MELAS present with stroke-like episodes, seizures, muscle weakness, and systemic manifestations such as lactic acidosis. Neurological abnormalities, including tic manifestations, can be part of the broader neuropsychiatric spectrum seen in mitochondrial disorders. Diagnosis is based on a combination of clinical features, laboratory evidence of lactic acidosis, and confirmatory studies such as muscle biopsy, which reveals ragged-red fibers and other mitochondrial abnormalities. Genetic testing for specific mitochondrial mutations can also provide definitive confirmation. Differential diagnoses include other mitochondrial encephalomyopathies and metabolic disorders that share overlapping features. Management of MELAS is primarily supportive and symptomatic. This involves the use of agents to manage seizures, stroke-like episodes (such as L-arginine during acute episodes), and metabolic derangements. There is no cure for MELAS, and treatment focuses on mitigating symptoms and improving quality of life. During pregnancy, patients require close monitoring due to risks of metabolic decompensation and potential fetal involvement; medications should be chosen with consideration given to fetal safety. In lactation, similar caution is advised with respect to drug exposures. Option B (Muscle Biopsy) is the correct choice because it allows for the identification of histopathologic features (e.g., ragged-red fibers) that are characteristic of MELAS. Option A (Skin Biopsy) is not typically useful in diagnosing MELAS, as the diagnostic abnormalities are principally found in muscle tissue. \u2022 Muscle biopsy revealing ragged-red fibers is a hallmark of MELAS. \u2022 MELAS often presents with stroke-like episodes and lactic acidosis in younger patients. \u2022 Mitochondrial disorders are maternally inherited, highlighting the importance of family history. Recent advances in genetic testing have improved diagnostic accuracy for MELAS, yet muscle biopsy remains crucial when genetic results are inconclusive. Current research emphasizes supportive management and the potential for novel therapies targeting mitochondrial dysfunction, although treatment remains largely symptomatic.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "The case for Fabry Disease diagnosis",
    "option_a": "Alpha galactosidase",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neurogenetics",
    "explanation": "Fabry disease is an X\u2010linked lysosomal storage disorder caused by a deficiency of the enzyme alpha-galactosidase A. This enzyme deficiency leads to the accumulation of glycosphingolipids, particularly globotriaosylceramide (Gb3), in various tissues. The reduced activity of alpha-galactosidase A results in the progressive buildup of Gb3 in endothelial, renal, cardiac, and neuronal cells. This accumulation triggers inflammation, cellular dysfunction, and ultimately tissue damage. The genetic basis is an X-linked mutation that explains the variable expression between males and females. Patients often present with episodes of pain (acroparesthesias), characteristic skin lesions (angiokeratomas), corneal opacities, and later may develop renal insufficiency, cardiomyopathy, and cerebrovascular complications. Early detection is important to limit irreversible organ damage. Diagnosis is typically confirmed by measuring alpha-galactosidase A enzyme activity (usually in leukocytes or plasma). Additional tests include genetic sequencing and assessment of Gb3 deposits in tissues. Differential diagnoses include other lysosomal storage diseases and small fiber neuropathies, but the combination of systemic features and enzyme assay results helps differentiate Fabry disease. Management includes enzyme replacement therapy (ERT) with recombinant alpha-galactosidase A (such as agalsidase alfa or beta) as first-line treatment. Adjunctive therapies may include pain management, angiotensin-converting enzyme inhibitors for renal protection, and cardiac care. For pregnant or lactating women, careful evaluation of the risk versus benefit of continuing ERT is recommended. Recent guidelines advise early initiation of therapy to reduce long-term complications. Option A, which calls for measuring alpha-galactosidase, is correct since enzyme assay is the fundamental diagnostic test for Fabry disease. The absence of other options does not affect the validity of the answer identified. 1) Always consider Fabry disease in patients with unexplained neuropathic pain, renal dysfunction, and angiokeratomas. 2) Early diagnosis and initiation of enzyme replacement therapy can slow or prevent organ damage. Recent studies underscore the benefits of early ERT initiation, which has been shown to reduce Gb3 deposition and improve long-term outcomes. Furthermore, newer adjunct approaches including pharmacological chaperones are under investigation for patients with amenable mutations.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "A young patient with Wilson disease how to treat",
    "option_a": "Something I can not recall",
    "option_b": "",
    "option_c": "orresponding to the established copper chelation agent.",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neurogenetics",
    "explanation": "Wilson disease is an autosomal recessive disorder of copper metabolism caused by mutations in the ATP7B gene. This results in impaired copper excretion, leading to its toxic accumulation mainly in the liver and brain. Defective copper-transporting ATPase (ATP7B) leads to decreased incorporation of copper into ceruloplasmin and impaired biliary excretion of copper. The resultant copper accumulation produces oxidative damage and cell death in the liver, brain, and other organs. Patients with Wilson disease may present with hepatic dysfunction (ranging from asymptomatic liver enzyme elevations to fulminant hepatic failure), neurological disorders (tremors, dysarthria, dystonia), psychiatric disturbances, and the classic Kayser-Fleischer rings on ophthalmologic examination. Diagnosis is based on low serum ceruloplasmin levels, increased urinary copper excretion, and the presence of Kayser-Fleischer rings. Differential diagnoses include other causes of liver disease and neuropsychiatric syndromes. Confirmatory tests include liver biopsy and genetic testing if the diagnosis remains uncertain. First-line treatment for Wilson disease is copper chelation. Traditionally, D-penicillamine is used to mobilize and promote the excretion of copper. If patients are intolerant to penicillamine, trientine is considered a second-line agent. Zinc may be used additionally, particularly as maintenance therapy or in presymptomatic cases. In neurological presentations, special caution is advised as penicillamine may initially worsen symptoms; some clinicians prefer trientine in these cases. During pregnancy, zinc is preferred because it is safer, but if chelation is required, penicillamine may be continued at a reduced dose with careful monitoring, as per current obstetric guidelines. The marked answer was B, but given the standard treatment algorithm, the first-line copper chelator for Wilson disease is D-penicillamine (which we assume is represented by option A in this question). Option B, without clear content, does not align with first-line management. Options C and D are not provided, making it essential to choose the option corresponding to the established copper chelation agent. 1) Early initiation of chelation therapy prevents irreversible organ damage in Wilson disease. 2) Neurological patients require careful management to avoid transient worsening with chelation therapy. Recent guidelines affirm D-penicillamine as the standard first-line treatment, although evolving practice may favor trientine in certain neurological presentations. Ongoing research into gene therapy may in the future provide additional options.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "Globoid cells;",
    "option_a": "Krabbe Disease",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neurogenetics",
    "explanation": "Globoid cells are a hallmark of Krabbe disease, which is also known as globoid cell leukodystrophy. This condition is a lysosomal storage disorder resulting from a deficiency in the enzyme galactocerebrosidase. The enzyme deficiency leads to the accumulation of psychosine, a toxic metabolite that results in the death of oligodendrocytes and subsequent demyelination. The presence of globoid cells (multinucleated macrophages) in the white matter is a pathological marker of this process. Infants with Krabbe disease typically present with irritability, spasticity, developmental regression, and muscle weakness. The rapid neurodegenerative course often leads to early death if untreated. Diagnosis involves clinical suspicion based on neurological findings, neuroimaging (MRI showing white matter changes), and the definitive measurement of galactocerebrosidase activity in leukocytes or fibroblasts. Differential diagnoses include other leukodystrophies and metabolic disorders, which can be differentiated by specific enzyme assay results. There is no definitive cure for Krabbe disease; management is mainly supportive. However, early intervention with hematopoietic stem cell transplantation (HSCT) has been shown to delay progression if initiated before significant neurological decline. For pregnant or lactating patients known to be carriers or in very rare circumstances where fetal intervention is considered, genetic counseling is key. Supportive therapies, including physical therapy and nutritional support, are also important. Option A, Krabbe Disease, is correct because globoid cells are pathognomonic for this condition. The lack of detail in options B, C, and D further reinforces that Option A is the best match. 1) Always consider Krabbe disease in infants with rapidly progressing neurodegeneration. 2) Early detection is critical as HSCT can only offer benefits if performed at a very early stage before severe neurological deterioration. Current research is focused on improving the outcomes of HSCT and exploring gene therapy options, which may hold promise for altering the disease course in the future.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "Scenario of symptoms suggestive of Fabry disease, what is the treatment?",
    "option_a": "agloucuside",
    "option_b": "L arginine",
    "option_c": "?",
    "option_d": "?",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neurogenetics",
    "explanation": "Fabry disease is an X-linked lysosomal storage disorder caused by a deficiency of alpha-galactosidase A, leading to the accumulation of glycosphingolipids. The treatment is aimed at replacing the missing enzyme to halt or reverse the pathogenic process. The enzyme deficiency results in the buildup of globotriaosylceramide (Gb3) within cells, particularly in vascular endothelial tissues, leading to inflammation, fibrosis, and eventual organ dysfunction. This accumulation affects various systems including the skin, kidney, heart, and nervous system. Clinically, Fabry disease can present with neuropathic pain (especially in the extremities), angiokeratomas, corneal opacities, gastrointestinal disturbances, and progressive renal and cardiac involvement. Early stage symptoms, if left untreated, may lead to irreversible organ damage. Diagnosis is confirmed by demonstrating reduced alpha-galactosidase A enzyme activity (typically in male patients) along with genetic testing. Differential diagnoses include other small fiber neuropathies and lysosomal storage disorders, but the constellation of cutaneous, renal, and cardiac findings along with laboratory tests help clinch the diagnosis. The cornerstone of treatment is enzyme replacement therapy (ERT) with recombinant alpha-galactosidase A preparations (commonly agalsidase alfa or agalsidase beta), which helps clear Gb3 deposits. Chaperone therapy (migalastat) is available for patients with amenable mutations. Pain management, renin-angiotensin system blockade for renal protection, and symptomatic treatment for cardiac issues are also important. In pregnancy, ERT is usually continued if the benefits outweigh the risks, and close monitoring is advised because safety data are still evolving; lactating mothers should consult current guidelines regarding the continuation of therapy. Option A, 'agloucuside', appears to be a typographical error intended to represent agalsidase (the enzyme replacement therapy used in Fabry disease). Option B, L-arginine, is not indicated in the treatment of Fabry disease. With the recognition that enzyme replacement therapy is the accepted treatment, Option A is correct. 1) Early initiation of ERT can prevent irreversible multi-organ damage in Fabry disease. 2) Always confirm the diagnosis with enzyme assay and genetic testing before initiating lifelong therapy. Recent studies and guidelines support the use of ERT, demonstrating improvements in renal function and reduction in cardiac events. Research into alternative treatment modalities, such as pharmacological chaperones and gene therapy, is ongoing and shows promise for the future management of Fabry disease.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "Case of fabry disease, asking about Rx?",
    "option_a": "Alpha galactosidase, enzyme replacement",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neurogenetics",
    "explanation": "Fabry disease is an X\u2010linked lysosomal storage disorder caused by deficient activity of the enzyme alpha\u2010galactosidase A. This deficiency leads to the accumulation of glycosphingolipids (mainly globotriaosylceramide) in various tissues including the vascular endothelium, heart, kidneys, and nervous system. Due to the mutation in the GLA gene, proper breakdown of glycosphingolipids does not occur. The resulting accumulation in lysosomes causes progressive damage to multiple organ systems. Recent research has emphasized the role of chronic vascular injury and inflammation as contributors to organ dysfunction in Fabry disease. Patients typically present with episodes of neuropathic pain (acroparesthesias), angiokeratomas on the skin, corneal verticillata, renal impairment, and cardiac complications. Early signs may include gastrointestinal disturbances and hypohidrosis. These clinical features are directly related to glycosphingolipid deposition. Diagnosis is based on clinical suspicion, enzyme assay (demonstrating decreased alpha\u2010galactosidase A activity), and confirmed by genetic testing (identification of mutations in the GLA gene). Differential diagnoses include other lysosomal storage disorders and atypical presentations of small fiber neuropathy. The first\u2010line treatment is enzyme replacement therapy (ERT) with recombinant alpha\u2010galactosidase A (such as agalsidase alfa or agalsidase beta). Additional supportive measures include pain management, ACE inhibitors or ARBs for renal protection, and cardiac monitoring. In pregnancy and lactation the data on ERT are limited, so therapy decisions require a careful risk\u2013benefit analysis in consultation with specialists. Option A (Alpha galactosidase, enzyme replacement) is correct because ERT directly addresses the enzyme deficiency in Fabry disease. Since no other options are provided, the marked answer is appropriate. 1) Early initiation of ERT may slow disease progression. 2) Look for characteristic skin lesions (angiokeratomas) and corneal deposits (cornea verticillata). 3) Remember its X\u2010linked inheritance which results in variable expression in females. Recent guidelines underscore the benefit of early ERT initiation to improve long\u2010term renal and cardiac outcomes. Ongoing research is investigating novel agents such as oral chaperone therapies and gene therapy to further modify disease progression.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "case of HD with CT brain showing head of caudate atrophy, asking about number of repeats in this patient?",
    "option_a": "48 CAG repeats",
    "option_b": "27 CAG repeats",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neurogenetics",
    "explanation": "Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder caused by an expanded CAG trinucleotide repeat in the HTT gene. It is one of several disorders resulting from repeat expansion mutations. The expansion leads to an abnormally long polyglutamine tract in the huntingtin protein, causing toxic gain-of-function effects. This results in selective neuronal death, particularly in the striatum (the caudate nucleus and putamen), thereby causing atrophy and characteristic movement disorders. Clinically, HD presents with chorea, psychiatric changes (depression, irritability), and progressive cognitive decline. Radiologically, atrophy of the head of the caudate nucleus is a hallmark finding, correlating with motor and cognitive dysfunction. Diagnosis is confirmed by genetic testing to determine the exact number of CAG repeats. A repeat count of 36\u201339 is associated with reduced penetrance, while 40 or more repeats (with many symptomatic patients in the 40\u201350 range, such as 48) signifies full penetrance. Differential diagnoses include other causes of chorea such as Wilson\u2019s disease, neuroacanthocytosis, and benign hereditary chorea. There is no cure for HD. Management is symptomatic with medications like tetrabenazine, deutetrabenazine, and antipsychotics to control chorea and mood disturbances. Multidisciplinary supportive care and genetic counseling are essential. In pregnancy, medication choices should be carefully considered due to teratogenic risks, and additional genetic counseling is imperative. Option A (48 CAG repeats) is correct, as this number falls within the range commonly seen in symptomatic HD patients and explains the radiological and clinical findings illustrated in the scenario. 1) HD typically shows caudate atrophy on imaging. 2) A CAG repeat count greater than 40 confirms disease with full penetrance. 3) The autosomal dominant inheritance makes family history a key element in diagnosis. Current research is focused on potential gene-silencing therapies and neuroprotective strategies. Although no disease-modifying treatments have been approved yet, advances in understanding the molecular mechanisms of HD are promising for future therapies.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "which of the following metabolic disease associated with bilateral subdural hematoma:",
    "option_a": "Nieman Pick",
    "option_b": "GLUT 1 >>> GA1",
    "option_c": "Marple syrup urine.",
    "option_d": "phenylketonuria",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neurogenetics",
    "explanation": "Glutaric Aciduria type I (GA1) is an inborn error of metabolism that affects the breakdown of lysine, hydroxylysine, and tryptophan due to a deficiency of glutaryl-CoA dehydrogenase. It is autosomal recessive and part of the organic acidurias. The enzyme deficiency leads to the accumulation of toxic organic acids (glutaric acid and 3-hydroxyglutaric acid) which can cause neuronal damage and compromise the integrity of cerebral vasculature. This accumulation predisposes affected individuals, especially in infancy, to brain injury and structural changes including bilateral subdural hematomas. Children with GA1 often present with macrocephaly, developmental delays, and movement disorders such as dystonia. In some cases, bilateral subdural hematomas are seen, which can mimic findings related to non-accidental head trauma. The hematomas are thought to be due to stretching or tearing of bridging veins secondary to brain structural changes. Diagnosis is made by urine organic acid analysis, which reveals elevated levels of glutaric acid and 3-hydroxyglutaric acid. Additional tests include enzyme assay for glutaryl-CoA dehydrogenase activity and genetic testing. Differential diagnoses include accidental trauma, other metabolic disorders like Niemann-Pick disease (which has different clinical and radiological profiles), and disorders such as maple syrup urine disease or phenylketonuria that do not typically demonstrate subdural collections. Management involves dietary restriction of lysine and tryptophan to reduce substrate accumulation and supplementation with carnitine to help remove toxic organic acids. During episodes of metabolic stress or illness, aggressive supportive management is required to prevent neurological damage. In pregnant or lactating women who are carriers or affected, careful dietary planning and metabolic monitoring are essential to balance maternal and fetal nutritional needs. Option A (Niemann-Pick) is incorrect as it does not typically present with bilateral subdural hematomas. Option B, although ambiguously labeled as 'GLUT 1', is intended to point toward GA1 (Glutaric Aciduria type I), which is the correct metabolic disorder associated with bilateral subdural hematomas. Option C (Maple Syrup Urine Disease) and Option D (Phenylketonuria) do not characteristically cause bilateral subdural hematomas. 1) GA1 should be considered in infants with macrocephaly and bilateral subdural hematomas to avoid misinterpretation as child abuse. 2) Early dietary intervention can significantly reduce neurological damage. 3) Newborn screening is pivotal in early diagnosis. Recent studies and updated clinical guidelines advocate for early dietary management and metabolic crisis prevention, which have led to improved neurodevelopmental outcomes. Enhanced newborn screening protocols continue to improve early detection and treatment initiation in GA1.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  },
  {
    "question": "Hallervorden-spatz syndrome, what's the gene:",
    "option_a": "PKAN-1",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neurogenetics",
    "explanation": "Hallervorden-Spatz syndrome, more accurately referred to as Pantothenate Kinase-Associated Neurodegeneration (PKAN), is a neurodegenerative disorder characterized by abnormal iron accumulation in the brain, particularly in the basal ganglia. The disorder is predominantly caused by mutations in the PANK2 gene, which encodes the enzyme pantothenate kinase 2. Its deficiency disrupts coenzyme A metabolism, leading to iron accumulation and subsequent neurotoxicity. The deposition of iron in the globus pallidus produces a characteristic 'eye-of-the-tiger' sign on MRI. Patients present with progressive extrapyramidal symptoms including dystonia, rigidity, and parkinsonism along with cognitive decline. The neuroimaging findings correlate well with the clinical presentation and help differentiate PKAN from other neurodegenerative disorders. The diagnosis is made based on clinical findings, characteristic MRI changes (the 'eye-of-the-tiger' sign), and confirmed with genetic testing demonstrating mutations in the PANK2 gene. Differential diagnoses include other forms of neurodegeneration with brain iron accumulation (NBIA) such as PLA2G6-associated neurodegeneration. There is currently no cure for PKAN. Management is palliative and primarily focused on symptomatic relief. Options include medications to control dystonia (anticholinergics, benzodiazepines), and in some cases, deep brain stimulation may be considered. For pregnant or lactating patients, treatment is supportive and the safety of specific symptomatic medications must be carefully weighed against potential fetal risks. Option A (PKAN-1) is considered correct. Although the preferred nomenclature is a mutation in the PANK2 gene, 'PKAN' (Pantothenate Kinase-Associated Neurodegeneration) is an accepted clinical term referring to the disorder. Other alternatives would be inappropriate if they do not relate to the underlying gene mutation. 1) The 'eye-of-the-tiger' sign is a key imaging clue in PKAN. 2) Although historically called Hallervorden-Spatz syndrome, current terminology favors PKAN due to improved genetic understanding. 3) Management remains symptomatic with no established disease-modifying therapy. Ongoing research is investigating iron chelation therapy and gene therapy as potential treatments. Recent reviews emphasize the need for multidisciplinary care and early engagement with supportive therapies to manage the progressive disability associated with PKAN.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  },
  {
    "question": "Patient with bitemporal hemianopia and headache with drop in Hgb (? BP):",
    "option_a": "Carotid cavernous fistula",
    "option_b": "Craniopharyngioma with a ruptured cyst.",
    "option_c": "Pituitary apoplexy",
    "option_d": "Subarachnoid hemorrhage",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Headache",
    "explanation": "Pituitary apoplexy is a sudden hemodynamic event (hemorrhage and/or infarction) within the pituitary gland, often occurring in a pre\u2010existing adenoma. It leads to rapid expansion in the sellar region that compresses adjacent structures such as the optic chiasm, producing visual field deficits like bitemporal hemianopia, as well as severe headache and sometimes endocrine crisis. The pathophysiology involves acute hemorrhage or infarction within a pituitary adenoma. Bleeding into the tumor can lead to a rapid increase in intrasellar pressure, causing compression of the optic chiasm and adjacent neural structures. The hemorrhagic event may also cause a drop in hemoglobin and trigger hemodynamic instability due to pituitary insufficiency and adrenal crisis if untreated. Risk factors include anticoagulation, major surgery, or situations of increased intracranial pressure. Patients typically present with a sudden, severe headache often described as \u201cthunderclap,\u201d visual disturbances (especially bitemporal hemianopia), ophthalmoplegia, and in some cases altered mental status. Endocrine abnormalities may manifest as hypotension (from acute adrenal insufficiency) and other hormonal deficits. The drop in Hgb suggests a significant hemorrhagic event within the gland. Diagnosis is primarily made with magnetic resonance imaging (MRI) employing a dedicated pituitary protocol. Differentials include carotid cavernous fistula (presents mainly with orbital signs and pulsatile exophthalmos), ruptured craniopharyngioma cyst (more common in children/young adults with cystic mass lesions), and subarachnoid hemorrhage (which typically presents with neck stiffness and a different pattern of bleeding on CT). Laboratory evaluation of pituitary function is also critical. Management involves prompt high-dose corticosteroids to address adrenal insufficiency and reduce edema, supportive care, and urgent neurosurgical evaluation. Indications for surgical decompression include worsening visual deficits and deteriorating neurological status. In pregnancy and lactation, management still prioritizes stabilization and administration of steroids, with careful selection of surgical intervention timing and technique to minimize risks to both mother and fetus. Option A (Carotid cavernous fistula) usually presents with pulsatile exophthalmos and ocular congestion. Option B (Craniopharyngioma with a ruptured cyst) typically affects the pediatric/young adult population and does not usually lead to an acute drop in Hgb. Option C (Pituitary apoplexy) correctly ties together the headache, bitemporal visual loss, and hemorrhagic presentation. Option D (Subarachnoid hemorrhage) presents with a sudden severe headache but is less likely to cause the specific visual field deficit described. 1. Sudden headache with visual deficits in a patient with a known or suspected pituitary adenoma should raise immediate suspicion for pituitary apoplexy. 2. Prompt corticosteroid therapy is essential to manage potential adrenal crisis. 3. MRI with a dedicated pituitary protocol is the imaging modality of choice. Recent endocrine and neurosurgical guidelines emphasize rapid diagnosis and treatment with glucocorticoids, with a multidisciplinary approach for patients with pituitary apoplexy. Current research is focused on identifying risk factors for hemorrhage in pituitary adenomas and optimizing timing for surgical intervention.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Scenario of SUNA and ask about the first line treatment",
    "option_a": "Lamotrigine",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "SUNA (Short-lasting Unilateral Neuralgiform headache attacks with cranial Autonomic symptoms) is part of the trigeminal autonomic cephalalgia spectrum. It is characterized by brief, frequent headache attacks accompanied by ipsilateral autonomic features such as lacrimation or nasal congestion. The exact mechanism is not completely understood but involves activation of the trigeminal-autonomic reflex. Dysfunction in hypothalamic pain modulation circuits and abnormal brainstem signaling are believed to play roles, similar to the pathophysiology implicated in SUNCT (Short-lasting Unilateral Neuralgiform headache attacks with Conjunctival injection and Tearing). Patients experience short-lasting attacks (from seconds to a few minutes) of unilateral facial pain along with autonomic signs. The frequent and brief attacks differentiate SUNA from other primary headache disorders such as migraine or cluster headache. Diagnosis is clinical, based on patient history and symptom characterization. Differential diagnoses include trigeminal neuralgia, cluster headache, and paroxysmal hemicrania. A detailed history helps differentiate SUNA from these by virtue of its duration, frequency, and accompanying autonomic symptoms. First-line treatment for SUNA is generally pharmacologic. Lamotrigine is commonly recommended based on evidence of its efficacy in reducing attack frequency and severity. Second-line therapies include topiramate, gabapentin, or other anticonvulsants. In the context of pregnancy and lactation, medication selection must balance efficacy with fetal safety \u2013 lamotrigine is often used cautiously in pregnant women, with monitoring of serum levels due to altered pharmacokinetics during pregnancy. Option A (Lamotrigine) is supported by clinical studies as a first-line option for SUNA given its favorable response profile. Other options were not provided, but among the potential treatments, lamotrigine is the most evidence\u2010backed. There is no indication in the stem to use alternatives immediately without first attempting lamotrigine. 1. SUNA attacks are brief and can be mistaken for other facial pain syndromes; correct identification of autonomic features is key. 2. Lamotrigine\u2019s slow titration schedule requires patient education regarding delayed onset of efficacy. 3. Monitoring for side effects is important, particularly in women of childbearing age. Recent studies and headache society guidelines continue to endorse lamotrigine as a first-line therapy for SUNA. Ongoing research into the pathophysiological mechanisms may further refine management strategies and explore novel therapeutic targets.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Scenario of trigeminal neuralgia, what you need to reach the diagnosis?",
    "option_a": "Brain MRI (Clinical diagnosis, no need for imaging)",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "Clinical diagnosis; no imaging required",
    "subspecialty": "Headache",
    "explanation": "Trigeminal neuralgia is a neuropathic pain syndrome characterized by sudden, brief, and recurrent shock\u2010like facial pain in the distribution of the trigeminal nerve. The diagnosis is primarily based on clinical history and symptom characteristics. The most common etiology in classic trigeminal neuralgia is vascular compression of the trigeminal nerve root, leading to demyelination and subsequent ephaptic transmission (cross-talk) of pain signals. Secondary causes include demyelinating diseases like multiple sclerosis or space\u2010occupying lesions that compress the nerve. Patients typically present with unilateral paroxysmal facial pain triggered by light touch, chewing, or even a breeze. The clinical presentation is often strikingly typical, and the absence of other neurologic deficits supports the diagnosis. Trigeminal neuralgia is largely a clinical diagnosis based on the patient\u2019s history and characteristic pain pattern. While high-resolution MRI (with and without contrast) is often used to exclude secondary causes such as multiple sclerosis or a compressive mass lesion, in a classic presentation without atypical features, imaging is not mandated solely for diagnosis. First-line therapy for trigeminal neuralgia is medical management with anticonvulsants such as carbamazepine or oxcarbazepine. MRI is recommended if there are atypical features, younger age at presentation, or treatment resistance, to rule out secondary causes. In pregnancy and lactation, carbamazepine is used with caution due to teratogenicity, and dose adjustments may be necessary with close monitoring. The marked answer states that the diagnosis is clinical and does not require imaging if the presentation is classic. Although current practice often includes MRI to rule out secondary causes (especially in younger patients or those with atypical features), for an exam question describing a typical presentation, the clinical diagnosis is acceptable. This option is therefore correct within the context of classic trigeminal neuralgia. 1. Trigeminal neuralgia is a clinical diagnosis, but always consider neuroimaging if red flags or atypical features are present. 2. Vascular compression is the most common etiology, making the role of imaging more about exclusion of secondary causes. 3. Treatment with anticonvulsants is effective in the majority of patients. Recent guidelines support the clinical diagnosis of classic trigeminal neuralgia while recognizing the role of MRI in excluding secondary causes. Advances in high-resolution imaging have improved the detection of neurovascular conflicts but have not replaced the core clinical diagnostic criteria.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Patient has hyperreflexia, headache, MRI showed diffuse with lesion. What you will do?",
    "option_a": "Skin biopsy",
    "option_b": "Muscle biopsy",
    "option_c": "Fibroblast chest x ray",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "The scenario suggests a patient with neurological signs (hyperreflexia, headache) and diffusely abnormal MRI findings, which can be seen in certain genetic small-vessel diseases such as CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy). CADASIL is caused by mutations in the NOTCH3 gene, leading to degeneration of vascular smooth muscle cells and deposition of granular osmiophilic material in the walls of small arterioles. This results in chronic ischemic damage, diffuse white matter changes on MRI, and progressive neurological deficits including migraine, strokes, and cognitive impairment. Hyperreflexia may be present as a sign of pyramidal tract involvement due to subcortical infarcts. Patients with CADASIL typically present with recurrent migraines (often with aura), subcortical ischemic events, and progressive cognitive decline. MRI usually reveals diffuse white matter hyperintensities, particularly in the periventricular and temporal regions. The presence of hyperreflexia may reflect upper motor neuron involvement from multiple lacunar infarcts. The gold standard for diagnosing CADASIL is genetic testing for NOTCH3 mutations. However, when genetic testing is not readily available or is inconclusive, a skin biopsy examined with electron microscopy can reveal the characteristic granular osmiophilic material in the vessel walls. Differential diagnoses include multiple sclerosis (demyelinating plaques with a relapsing-remitting course) and other leukodystrophies; these can be differentiated by clinical history, age of onset, and specific imaging findings. There is no definitive treatment for CADASIL; management is primarily supportive and focused on controlling vascular risk factors. Antiplatelet agents may be used for stroke prevention, and migraine management is symptomatic. In pregnancy and lactation, management remains supportive with careful control of blood pressure and individualized risk assessment, as many of the medications used in stroke prevention require caution during pregnancy. Option A (Skin biopsy) is the correct option to help establish a diagnosis when genetic testing is not available, as it can demonstrate the granular osmiophilic material characteristic of CADASIL. Option B (Muscle biopsy) is unrelated to the diagnosis of cerebral small vessel disease. Option C (Fibroblast chest x ray) is not a recognized diagnostic tool in this scenario. 1. CADASIL should be suspected in patients with early-onset migraine, strokes, and diffuse white matter changes on MRI. 2. While genetic testing is the gold standard, a skin biopsy can support the diagnosis by revealing granular osmiophilic material. 3. Management is predominantly supportive, with aggressive risk factor control. The latest research emphasizes the importance of genetic confirmation for CADASIL; however, skin biopsy remains useful in resource-limited settings. Current guidelines advocate for cardiovascular risk management and symptomatic treatment, and ongoing studies are investigating targeted therapies to modify disease progression.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Female with migraine once a month did brain MRI and showed (picture has 2 small white matter non-specific lesions in each hemisphere) what to do next:",
    "option_a": "CTA",
    "option_b": "Reassurance.",
    "option_c": "Methylprednisolone.",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Headache",
    "explanation": "In migraine patients, incidental small nonspecific white matter lesions on MRI are frequently encountered and are not indicative of an alternative diagnosis when the clinical picture is typical for migraine. Migraine-associated white matter changes may reflect microvascular alterations or transient disruptions in small vessels from repeated migraine attacks. These lesions are nonspecific and do not indicate an active demyelinating or inflammatory process. A patient with episodic migraine who shows two small white matter lesions without other neurological deficits is exhibiting a common, benign MRI finding in migraine. There is no clinical evidence of diseases like multiple sclerosis that would warrant further aggressive investigation or treatment. Differential diagnoses for white matter lesions include demyelinating disorders (eg, multiple sclerosis), small vessel ischemic disease, and migraine-related changes. Integration of clinical history, absence of progressive neurological symptoms, and the pattern of lesions on imaging aid in differentiation. The recommended approach is reassurance and continuation of standard migraine management. No further vascular imaging (eg, CTA) or immunosuppressive therapy (eg, methylprednisolone) is indicated. In special populations such as pregnant or lactating patients, conservative management is preferred with headache-specific treatments adjusted for safety. Option A (CTA) is inappropriate because vascular imaging is not indicated in typical migraine-related white matter changes. Option B (Reassurance) is correct given that these lesions are benign incidental findings. Option C (Methylprednisolone) is not indicated as there is no evidence of an inflammatory disorder. 1. Incidental white matter hyperintensities are commonly seen in migraine and are typically benign. 2. Always correlate imaging findings with the patient\u2019s clinical history. 3. Avoid unnecessary further testing when imaging findings are consistent with migraine. Recent studies confirm that small nonspecific white matter lesions in migraine patients are benign and do not predict future neurological decline, supporting a conservative management approach.",
    "exam_year": "2018",
    "exam_type": "Part I",
    "image_url": "https://drive.google.com/file/d/1f9uvNEVxWbedtNj5HxXq2t3Tzuv8ViHY/preview"
  },
  {
    "question": "Treatment of hypnic headache:",
    "option_a": "Lithium",
    "option_b": "Oxygen",
    "option_c": "Amitriptyline",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "In migraine patients, incidental small nonspecific white matter lesions on MRI are frequently encountered and are not indicative of an alternative diagnosis when the clinical picture is typical for migraine. Migraine-associated white matter changes may reflect microvascular alterations or transient disruptions in small vessels from repeated migraine attacks. These lesions are nonspecific and do not indicate an active demyelinating or inflammatory process. A patient with episodic migraine who shows two small white matter lesions without other neurological deficits is exhibiting a common, benign MRI finding in migraine. There is no clinical evidence of diseases like multiple sclerosis that would warrant further aggressive investigation or treatment. Differential diagnoses for white matter lesions include demyelinating disorders (eg, multiple sclerosis), small vessel ischemic disease, and migraine-related changes. Integration of clinical history, absence of progressive neurological symptoms, and the pattern of lesions on imaging aid in differentiation. The recommended approach is reassurance and continuation of standard migraine management. No further vascular imaging (eg, CTA) or immunosuppressive therapy (eg, methylprednisolone) is indicated. In special populations such as pregnant or lactating patients, conservative management is preferred with headache-specific treatments adjusted for safety. Option A (CTA) is inappropriate because vascular imaging is not indicated in typical migraine-related white matter changes. Option B (Reassurance) is correct given that these lesions are benign incidental findings. Option C (Methylprednisolone) is not indicated as there is no evidence of an inflammatory disorder. 1. Incidental white matter hyperintensities are commonly seen in migraine and are typically benign. 2. Always correlate imaging findings with the patient\u2019s clinical history. 3. Avoid unnecessary further testing when imaging findings are consistent with migraine. Recent studies confirm that small nonspecific white matter lesions in migraine patients are benign and do not predict future neurological decline, supporting a conservative management approach.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "25-year-old female with history of type 1 DM, she has migraine once a month, lasts more than 24 hours. She is in her final year in university, what will you give her for prophylaxis?",
    "option_a": "Amitriptyline",
    "option_b": "Topiramate",
    "option_c": "Carbamazepine",
    "option_d": "Propranolol.",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Headache",
    "explanation": "In migraine patients, incidental small nonspecific white matter lesions on MRI are frequently encountered and are not indicative of an alternative diagnosis when the clinical picture is typical for migraine. Migraine-associated white matter changes may reflect microvascular alterations or transient disruptions in small vessels from repeated migraine attacks. These lesions are nonspecific and do not indicate an active demyelinating or inflammatory process. A patient with episodic migraine who shows two small white matter lesions without other neurological deficits is exhibiting a common, benign MRI finding in migraine. There is no clinical evidence of diseases like multiple sclerosis that would warrant further aggressive investigation or treatment. Differential diagnoses for white matter lesions include demyelinating disorders (eg, multiple sclerosis), small vessel ischemic disease, and migraine-related changes. Integration of clinical history, absence of progressive neurological symptoms, and the pattern of lesions on imaging aid in differentiation. The recommended approach is reassurance and continuation of standard migraine management. No further vascular imaging (eg, CTA) or immunosuppressive therapy (eg, methylprednisolone) is indicated. In special populations such as pregnant or lactating patients, conservative management is preferred with headache-specific treatments adjusted for safety. Option A (CTA) is inappropriate because vascular imaging is not indicated in typical migraine-related white matter changes. Option B (Reassurance) is correct given that these lesions are benign incidental findings. Option C (Methylprednisolone) is not indicated as there is no evidence of an inflammatory disorder. 1. Incidental white matter hyperintensities are commonly seen in migraine and are typically benign. 2. Always correlate imaging findings with the patient\u2019s clinical history. 3. Avoid unnecessary further testing when imaging findings are consistent with migraine. Recent studies confirm that small nonspecific white matter lesions in migraine patients are benign and do not predict future neurological decline, supporting a conservative management approach.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "A patient came with history of unilateral headache, severe, less than 5 minutes, stabbing pain, unilateral, associated with autonomic symptoms on the same side (tearing.), what\u2019s the diagnosis?",
    "option_a": "Short-lasting unilateral neuralgiform headache with conjunctival injection and tearing (SUNCT)",
    "option_b": "Hemicrania continua",
    "option_c": "Chronic paroxysmal hemicrania",
    "option_d": "Cluster headache",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "In migraine patients, incidental small nonspecific white matter lesions on MRI are frequently encountered and are not indicative of an alternative diagnosis when the clinical picture is typical for migraine. Migraine-associated white matter changes may reflect microvascular alterations or transient disruptions in small vessels from repeated migraine attacks. These lesions are nonspecific and do not indicate an active demyelinating or inflammatory process. A patient with episodic migraine who shows two small white matter lesions without other neurological deficits is exhibiting a common, benign MRI finding in migraine. There is no clinical evidence of diseases like multiple sclerosis that would warrant further aggressive investigation or treatment. Differential diagnoses for white matter lesions include demyelinating disorders (eg, multiple sclerosis), small vessel ischemic disease, and migraine-related changes. Integration of clinical history, absence of progressive neurological symptoms, and the pattern of lesions on imaging aid in differentiation. The recommended approach is reassurance and continuation of standard migraine management. No further vascular imaging (eg, CTA) or immunosuppressive therapy (eg, methylprednisolone) is indicated. In special populations such as pregnant or lactating patients, conservative management is preferred with headache-specific treatments adjusted for safety. Option A (CTA) is inappropriate because vascular imaging is not indicated in typical migraine-related white matter changes. Option B (Reassurance) is correct given that these lesions are benign incidental findings. Option C (Methylprednisolone) is not indicated as there is no evidence of an inflammatory disorder. 1. Incidental white matter hyperintensities are commonly seen in migraine and are typically benign. 2. Always correlate imaging findings with the patient\u2019s clinical history. 3. Avoid unnecessary further testing when imaging findings are consistent with migraine. Recent studies confirm that small nonspecific white matter lesions in migraine patients are benign and do not predict future neurological decline, supporting a conservative management approach.",
    "exam_year": "2018",
    "exam_type": "Part I"
  }
]